Marketed as a powerful weight-loss solution, this injectable supplement claims to accelerate fat burning, improve energy levels, and enhance muscle definition
The largest one is a phase 3, double-blind trial, by Novo Nordisk, aspiring to recruit 1,200 patients with NASH, with or without DM2, expected to be completed in 2028 (NCT04822181)
Serious but rare adverse events include pancreatitis, gallbladder disease, acute kidney injury, and hypersensitivity reactions
This means less nausea at peak, more consistent appetite suppression at trough, and a generally smoother experience throughout the week
Ingredientes Natural Ingredients Advertencia de seguridad No See more Package includes: 1/2/3 boxes * Nano-microneedle patch